Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized withdrawal extension study of bimagrumab in older adults with sarcopenia
jRCT2080223245Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial of bimagrumab in Sarcopenia (4 arms), sponsored by Novartis. Primary endpoints: Durability of effect on skeletal muscle strength and Durability of effect on physical function. Started Jun 2016; status: completed.
02
Drugs
bimagrumab
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on jRCT2080223245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223245.